Examination of universal microhardness of liard reaction layers resulting from reactions of organic polymers with container glass surfaces and their use for low-friction protective layers

Clear, highly alkaline and wear-resistant hard reaction layers are formed by direct alkaline coupling of organic polymers with functional groups, particularly high-molecular polyols, to siliceous glass surfaces having container glass compositions. As compared with untreated glass these are characterized by an increased universal hardness and an excellent scratch resistance. Formation of these layers requires a highly alkahne reaction medium, e.g. 2% NaOH, 85°C, according to the conditions of the alkaline washing process of returnable beverage bottles in the bottling plants. It can be assumed that the formation of the reaction layer is associated with the formation of highly molecular ionic polymers with 5-coordinated silicon. Results of universal microhardness measurements of the hard reaction layers which were formed with aqueous polymer dispersions (epoxy resin microdispersion; low-molecular oxidized polyethylene) are presented. The increase of plastic universal hardness in comparison with untreated glass demonstrates the enhanced wear resistance of these layers. So far layer thicknesses up to 0.3 µm could be achieved. These results suggest new approaches to develop highly efficient low-friction protective layers for returnable bottles, and after increasing the thickness of the hard reaction layer up to several micrometers, they could possibly be applied also to lightweight bottles under enhanced internal pressure as used for carbonated beverages. Universal microhardness measurements are a very useful tool in the development and most effective improvement of such novel low-friction protective coatings for container glass

Supportive Care During Pediatric Hematopoietic Stem Cell Transplantation : Prevention of Infections. A Report From Workshops on Supportive Care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Specific protocols define eligibility, conditioning, donor selection, graft composition and prophylaxis of graft vs. host disease for children and young adults undergoing hematopoietic stem cell transplant (HSCT). However, international protocols rarely, if ever, detail supportive care, including pharmaceutical infection prophylaxis, physical protection with face masks and cohort isolation or food restrictions. Supportive care suffers from a lack of scientific evidence and implementation of practices in the transplant centers brings extensive restrictions to the child's and family's daily life after HSCT. Therefore, the Board of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) held a series of dedicated workshops since 2017 with the aim of initiating the production of a set of minimal recommendations. The present paper describes the consensus reached within the field of infection prophylaxis.Peer reviewe

Hematopoietic cell transplantation in severe combined immunodeficiency : The SCETIDE 2006-2014 European cohort

Publisher Copyright: © 2021 The AuthorsBackground: Hematopoietic stem cell transplantation (HSCT) represents a curative treatment for patients with severe combined immunodeficiency (SCID), a group of monogenic immune disorders with an otherwise fatal outcome. Objective: We performed a comprehensive multicenter analysis of genotype-specific HSCT outcome, including detailed analysis of immune reconstitution (IR) and the predictive value for clinical outcome. Methods: HSCT outcome was studied in 338 patients with genetically confirmed SCID who underwent transplantation in 2006-2014 and who were registered in the SCETIDE registry. In a representative subgroup of 152 patients, data on IR and long-term clinical outcome were analyzed. Results: Two-year OS was similar with matched family and unrelated donors and better than mismatched donor HSCT (P 0.5 × 10e3/μL at +1 year were identified as independent predictors of favorable clinical and immunologic outcome. Conclusion: Recent advances in HSCT in SCID patients have resulted in improved OS and EFS in all genotypes and donor types. To achieve a favorable long-term outcome, treatment strategies should aim for optimal naive CD4 T lymphocyte regeneration.Peer reviewe

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.https://deepblue.lib.umich.edu/bitstream/2027.42/144529/1/12967_2018_Article_1552.pd